Is Semaglutide Peptide the Same as Ozempic?

Semaglutide is the peptide; Ozempic is one of its brand names

Semaglutide is a synthetic analogue of GLP-1, a gut hormone the body naturally releases after eating. It slows stomach emptying, reduces appetite signals in the brain, and helps regulate blood sugar. Novo Nordisk developed the molecule and brought it to market under two brand names for two distinct conditions.

Ozempic came first, a once-weekly injection licensed to help people with type 2 diabetes control blood glucose. The dosing pathway for Ozempic runs up to 1 mg (and 2 mg in some markets), and the clinical trials behind it were designed around blood-sugar outcomes, not weight. You can read more about how semaglutide works across its different forms on our semaglutide overview page.

Wegovy uses the same peptide but at a higher maintenance dose (2.4 mg weekly as standard, rising to 7.2 mg with the pen the MHRA approved in April 2026) and the trial programme behind it (the STEP studies) was built around weight reduction in people with obesity or overweight plus a weight-related condition. That's the distinction that changes the licence, the prescribing context, and what a regulated UK clinic can offer you. The Wegovy page has the full picture on UK eligibility and what to expect from treatment.

If you've seen the term "semaglutide peptide" in research papers or on supplement websites, it usually refers to the raw molecule before it's formulated into a medicinal product, and our page on whether Ozempic is semaglutide or a tripeptide explains exactly how those terms relate to one another. The licensed injectable medicines contain semaglutide in a pharmaceutical-grade formulation with a specific delivery mechanism. Research peptides sold online are an entirely separate category and are not the same as licensed medicines.

What the UK licence means, and why it's not just paperwork

You might reasonably wonder: if Ozempic and Wegovy contain the same molecule, does the licence really matter? For a patient it matters considerably. The MHRA grants a licence based on the evidence submitted for a specific indication at a specific dose. Prescribing outside that licence is off-label, which isn't illegal (doctors do it in certain situations) but it shifts the clinical responsibility entirely onto the prescriber and removes the standardised evidence base that governs dosing, monitoring and stopping criteria.

For weight management specifically, the NHS patient information for semaglutide is clear that Wegovy is the weight-loss form. Ozempic's licence does not include weight management. NICE's appraisal of semaglutide for weight loss (TA875) refers throughout to Wegovy, not Ozempic, for a reason: it evaluated the evidence submitted for the weight-loss licence at the weight-loss dose.

We hear from people who were offered Ozempic by an unregulated seller and assumed the two were interchangeable. They're related, but that doesn't make them equivalent for this purpose. A registered UK pharmacy working within its clinical and regulatory obligations prescribes the licensed product for the licensed indication, which for weight loss means Wegovy, or tirzepatide (Mounjaro). If you're comparing the two weight-loss options, the comparison of Wegovy and Ozempic covers the practical differences plainly.

What is actually licensed for weight loss in the UK

Two injectable medicines currently hold a UK licence for weight management in adults: semaglutide as Wegovy, and tirzepatide as Mounjaro. Both are prescription-only medicines. Both require clinical assessment before a prescriber can issue a prescription.

Wegovy is licensed for adults with a BMI of 30 or above, or 27 or above where at least one weight-related condition is present, conditions such as high blood pressure, type 2 diabetes, high cholesterol, or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. NICE recommends Wegovy (TA875) within specialist weight management services for a maximum of two years. The STEP 1 trial, published in the New England Journal of Medicine, reported an average weight reduction of around 15% at 2.4 mg over 68 weeks.

Mounjaro (tirzepatide) is a dual GIP and GLP-1 receptor agonist (a different mechanism from semaglutide) and NICE recommends it (TA1026) for adults with a BMI of 35 or above and at least one weight-related comorbidity. The SURMOUNT head-to-head trial found tirzepatide produced greater average weight loss than semaglutide 2.4 mg over 72 weeks. Neither medicine is right for everyone; eligibility depends on the full clinical picture, which is exactly what a prescriber assesses. If you'd like to explore which option suits your situation, our free consultation is the place to start.

As for cost context: private weight-loss treatment pricing varies by product and dose. Our guide to Wegovy costs in the UK explains what drives the price differences and what a legitimate prescription service actually includes. That's worth reading before you make any decisions based on headline figures alone.

Ozempic for weight loss, the honest answer

People do lose weight on Ozempic. Semaglutide reduces appetite regardless of which brand name is on the pen. But Ozempic is not how a regulated UK weight-loss service should be prescribing semaglutide for weight management, for the reasons above. The dose isn't calibrated for weight loss. The monitoring protocol isn't designed for it. And the evidence base that regulators and NICE evaluated was built for Wegovy, not Ozempic.

If a seller is offering Ozempic specifically for weight loss, without a thorough clinical assessment and without being transparent about the off-label nature of the use, that's worth questioning. The MHRA has been clear that GLP-1 medicines should not be used for quick or cosmetic weight loss, and that buying these medicines from unverified sources carries real risk. You can read more about Ozempic's actual licence and role on this site, or browse our FAQs if you have a specific question our prescribers haven't answered here.

It's understandable to feel confused, the same name, the same molecule, different rules. That confusion is what well-structured clinical assessment is designed to cut through.